Seelos Therapeutics, Inc.

Seelos Therapeutics, Inc. is a clinical-stage biopharmaceutical company specializing in the development and commercialization of therapeutics for central nervous system, respiratory, and other disorders. The company's lead programs include SLS-002, an intranasal racemic ketamine for treating acute suicidal ideation in patients with major depressive disorders; SLS-005, a protein stabilizer for amyotrophic lateral sclerosis and Sanfilippo syndrome; and SLS-006, a partial dopamine agonist for Parkinson's disease. Additionally, Seelos has preclinical programs targeting PD, chronic inflammation in asthma, narcolepsy, and post-operative pain management.

Products

• SLS-002 (intranasal racemic ketamine)

• SLS-005 (protein stabilizer)

• SLS-006 (partial dopamine agonist)

• Preclinical programs targeting various disorders